a) If you are being treated for non-Hodgkin's lymphoma
a) If you are being treated for non-Hodgkin's lymphoma
In many cases, people who develop NHL have no risk factors, and doctors seldom know why one person develops non-Hodgkin's lymphoma and another does not.
The invention provides methods of treating non-small cell lung cancer (NSCLC) and non-hodgkin's lymphoma (NHL).
Preferably the cancer is chronic lymphocytic leukaemia, mantle cell lymphoma or non-Hodgkin's lymphoma.
In many cases, people who develop NHL have no risk factors, and doctors seldom know why one person develops non-Hodgkin’s lymphoma and another does not.
In the same email, Alavanja referred to the findings on non-Hodgkin lymphoma, or NHL.
It is a form of extranodal non-Hodgkin lymphoma (NHL) and appears at a median age of 62 years.
Thus, 30 candidates are clinically active in non-Hodgkin's lymphoma (NHL) and 26 in non-small cell lung cancer (NSCLC).
A new drug application (NDA) for idelalisib was submitted for refractory indolent non-Hodgkin’s lymphoma (iNHL) in September 2013.
follicular lymphoma and diffuse large B cell non-Hodgkin’s lymphoma (two types of non-Hodgkin’s lymphoma, a blood cancer);
follicular lymphoma and diffuse large B cell non-Hodgkin’s lymphoma (two types of non-Hodgkin’s lymphoma, a blood cancer)
follicular lymphoma and diffuse large B cell non-Hodgkin’s lymphoma (two types of non-Hodgkin’s lymphoma, a blood cancer)
follicular lymphoma and diffuse large B cell non-Hodgkin’s lymphoma (two types of non-Hodgkin’s lymphoma, a blood cancer);
Patients with multiply relapsed or refractory Hodgkin’s or non-Hodgkin’s lymphoma have limited treatment options.
Patients with multiply relapsed or refractory Hodgkin's or non-Hodgkin's lymphoma have limited treatment options.
For non-Hodgkin lymphoma, treatments are based on the type of non-Hodgkin lymphoma diagnosed, its stage, and the symptoms present, if any.
a) If you are being treated for non-Hodgkin’s Lymphoma
a) If you are being treated for non-Hodgkin’s Lymphoma
1997: The antibody rituximab is approved to treat non-Hodgkin’s lymphoma.
a 31 percent higher non-Hodgkin lymphoma risk (in men only)
This invention provides the use of a combination of CCI-779 and rituximab in the treatment of non-Hodgkin’s lymphoma.
About 30% higher risk of developing non-Hodgkin lymphoma (only in men)
No one really knows what causes non-Hodgkin lymphoma.
1997: The antibody rituximab is approved to treat non-Hodgkin’s lymphoma.
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод